GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gala Pharmaceutical Inc (OTCPK:GLPH) » Definitions » Net Income

Gala Pharmaceutical (Gala Pharmaceutical) Net Income : $-3.57 Mil (TTM As of May. 2019)


View and export this data going back to 2011. Start your Free Trial

What is Gala Pharmaceutical Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Gala Pharmaceutical's Net Income for the three months ended in May. 2019 was $-2.11 Mil. Its Net Income for the trailing twelve months (TTM) ended in May. 2019 was $-3.57 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Gala Pharmaceutical's Earnings per Share (Diluted) for the three months ended in May. 2019 was $-0.02.


Gala Pharmaceutical Net Income Historical Data

The historical data trend for Gala Pharmaceutical's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gala Pharmaceutical Net Income Chart

Gala Pharmaceutical Annual Data
Trend Nov11 Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18
Net Income
Get a 7-Day Free Trial -0.28 -0.68 -0.17 -1.98 -1.86

Gala Pharmaceutical Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.71 -0.17 -0.58 -2.11

Gala Pharmaceutical Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Gala Pharmaceutical's Net Income for the fiscal year that ended in Nov. 2018 is calculated as

Net Income(A: Nov. 2018 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.906+0+0+0.047
=-1.86

Gala Pharmaceutical's Net Income for the quarter that ended in May. 2019 is calculated as

Net Income(Q: May. 2019 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-2.131+0+0+0.018
=-2.11

Net Income for the trailing twelve months (TTM) ended in May. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gala Pharmaceutical  (OTCPK:GLPH) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Gala Pharmaceutical's Earnings per Share (Diluted) (EPS) for the quarter that ended in May. 2019 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Gala Pharmaceutical Net Income Related Terms

Thank you for viewing the detailed overview of Gala Pharmaceutical's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Gala Pharmaceutical (Gala Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
18881 Von Karman Avenue, Suite 1440, Irvine, CA, USA, 92612
Gala Pharmaceutical Inc is a United States-based company engaged in the hemp and cannabidiol (CBD) industry. It is focused on the development, research, and commercialization of products derived from the hemp and cannabis plant. It is focused on CBD flavored thin-film strip which is an advanced method of providing CBD for the dietary supplement. The services offered by the company are the development of cannabinoid-based health and wellness products; development of medical grade compounds; licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. The group earns revenue from the sale of products related to hemp and CBD, including modified electronic cigarettes and vape pens.